Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial

JULIAN CARLOS DE LA TORRE CISNEROSELENA PÉREZ NADALES2026-01-292026-01-29202310.1093/ofid/ofad1332-s2.0-85159591832https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/36420Infectious DiseasesOncologyRole of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trialresearch article